National press highlights the efficacy of Evusheld

09 November 2022

Following a number of clinical trails, the national media has highlighted the evidence that Evusheld is effective for protecting clinically extremely vulnerable people from covid-19.

Find the stories below:

BMJ, 08 Nov 2022 - Covid-19: Evusheld protects the most vulnerable patients, analysis shows

Mirror, 08 Nov 2022 - Breakthrough Covid drug for vulnerable proven to save lives - but it's not free on NHS

Evening Standard, 08 Nov 2022 - Antibody treatment could give clinically vulnerable people ‘revolutionary’ protection against Covid

back

We use cookies on appg-vulnerablegroups.org (e.g. tracking and analytical cookies), with which an analysis and measurement of user data is possible. Further information can be found in the Data Protection Declaration.

Mandatory

These cookies are needed for a smooth operation of our website.

Name	Purpose	Lifetime	Type	Provider
CookieConsent	Saves your consent to using cookies.	1 year	HTML	Website

analytics

Name	Purpose	Lifetime	Type	Provider
_ga	Used to distinguish users.	2 years	HTML	Google
_gat	Used to throttle request rate.	1 day	HTML	Google
_gid	Used to distinguish users.	1 day	HTML	Google
_ga_--container-id--	Persists session state.	2 years	HTML	Google
_gac_--property-id--	Contains campaign related information for the user. If you have linked your Google Analytics and Google Ads accounts, Google Ads website conversion tags will read this cookie unless you opt-out.	3 months	HTML	Google